BSEM
BioStem Technologies, Inc.
There isn't enough reported data to score BSEM yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
BSEM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Strong |
BSEM's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BSEM PE Valuation
BSEM has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BSEM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect BSEM's losses to grow, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BSEM on the outlook, with more favorable earnings and revenue expectations.
BSEM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.35 | -387% |
| Q2 2026 | -$1.68 | -251% |
| Q1 2026 | -$1.18 | -183% |
| Q4 2025 | -$0.49 | -134% |
| Q3 2025 | $0.82 | +34% |
| Q2 2025 | $1.11 | +247% |
| Q1 2025 | $1.43 | +$1.63 |
| Q4 2024 | $1.43 | +$1.94 |
BSEM has swung to a loss: it lost $2.35 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BSEM on earnings quality, reporting a profit while its opponent remains loss making.
BSEM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.6M | -27% |
| Q2 2026 | $7.9M | -84% |
| Q1 2026 | $6.1M | -92% |
| Q3 2025 | $10.5M | -87% |
| Q2 2025 | $49.3M | -34% |
| Q1 2025 | $72.5M | +73% |
| Q4 2024 | $102.9M | +799% |
| Q3 2024 | $82.6M | +2194% |
BSEM's revenue has slid since its 2024 peak: $8M last quarter, down 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -128% | -142 points |
| Q2 2026 | -106% | -107 points |
| Q1 2026 | -145% | -152 points |
| Q3 2025 | 14% | +2.6 points |
| Q2 2025 | 0.2% | -12 points |
| Q1 2025 | 7.2% | -3.8 points |
| Q4 2024 | 8.2% | +33 points |
| Q3 2024 | 11% | -3.5 points |
BSEM's operating margin was −128% last quarter, down 128 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BSEM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BSEM on profitability, with a higher operating margin.
BSEM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.8M | -$4M |
| Q1 2026 | -$827.3K | -121% |
| Q4 2025 | $2.4M | -70% |
| Q3 2025 | -$4.8M | -152% |
| Q2 2025 | $5.1M | -18% |
| Q1 2025 | $3.9M | +622% |
| Q4 2024 | $8M | +$9.4M |
| Q3 2024 | $9.3M | +$9.8M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with BSEM at down 371%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
BSEM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +537K shares |
| 1 year | -23% | -5.4M shares |
| 3 years | +32% | +4.4M shares |
| 5 years | +93% | +8.6M shares |
| Available history | +94% | +8.7M shares |
BSEM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $1.00 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BSEM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.2x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.6x | Net Cash |
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -0.2x | Net Cash |
| Q1 2024 | 19.3x | High |
BSEM has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BSEM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 3.2 | Oversold |
BSEM's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BSEM PE vs Healthcare Sector
| Metric | BSEM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BSEM has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BSEM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.07 | 37% below |
| 20 week MA | $3.08 | 58% below |
| 50 week MA | $4.09 | 68% below |
| 100 week MA | $7.27 | 82% below |
| 200 week MA | $6.91 | 81% below |
BSEM is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BSEM on trend strength, trading above more of its moving averages.
BSEM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.50 | $1.40 | -44% |
| 2021 | $1.40 | $1.10 | -21% |
| 2022 | $1.10 | $3.48 | +216% |
| 2023 | $3.48 | $5.86 | +68% |
| 2024 | $5.86 | $12.7 | +116% |
| 2025 | $12.7 | $3.87 | -69% |
| 2026 YTD | $3.87 | $1.30 | -66% |
BSEM's yearly returns have swung widely, from +216% in 2022 to −69% in 2025. It's down 66% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BSEM on returns for 2026, with the stronger performance.